If confirmed by long term analysis, this finding could provide ophthalmologists a new way to identify and treat those people who are most susceptible to vision reduction from glaucoma. The study was published online by Ophthalmology, the journal of the American Academy of Ophthalmology. Open-angle glaucoma , the most common type of the disease, affects three million people in the U nearly.S and 60 million worldwide. Vision loss occurs when glaucoma damages the optic nerve, the proper portion of the eye that transmits images from the retina to the brain. Unfortunately, because glaucoma doesn’t have symptoms, many people don't know the condition is had by them until an excellent portion of their sight has been lost.AVYCAZ ought to be reserved for use in patients who’ve limited or no alternative treatment options. A single-dose program of DALVANCE is definitely in late-stage development for ABSSSI, with a supplemental New Drug Program filing anticipated by mid-2015. THE BUSINESS is also studying DALVANCE in pediatric and adult osteomyelitis and endocarditis. Women's Health: Industry-Leading PRODUCTS Liletta – contraception LILETTA can be an Intrauterine Gadget , designed to initially deliver 20 mcg of levonorgestrel each day for the indications of long term contraception.